Related references
Note: Only part of the references are listed.Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)
G. Schernthaner et al.
DIABETES OBESITY & METABOLISM (2015)
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Faiez Zannad et al.
LANCET (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mortality risk among sulfonylureas: a systematic review and network meta-analysis
Scot H. Simpson et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? Yes, They Continue to Serve Us Well!
Martin J. Abrahamson
DIABETES CARE (2015)
Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It's Time to Move On!
Saul Genuth
DIABETES CARE (2015)
Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study
Evangelos Kontopantelis et al.
DIABETOLOGIA (2015)
Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997-2012
Lydia W. Turner et al.
DIABETES CARE (2014)
HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
Bo Ahren et al.
DIABETES CARE (2014)
Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study
S. Del Prato et al.
DIABETES OBESITY & METABOLISM (2014)
Association Between Intensification of Metformin Treatment With Insulin vs Sulfonylureas and Cardiovascular Events and All-Cause Mortality Among Patients With Diabetes
Christianne L. Roumie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes Reply
Mark J. Bolland et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
Martin Ridderstrale et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial
Juan C. Arjona Ferreira et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2013)
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial
Julio Rosenstock et al.
DIABETES & VASCULAR DISEASE RESEARCH (2013)
Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
Juan Camilo Arjona Ferreira et al.
DIABETES CARE (2013)
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Jie Hong et al.
DIABETES CARE (2013)
Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
David M. Nathan et al.
DIABETES CARE (2013)
Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2013)
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis
O. J. Phung et al.
DIABETIC MEDICINE (2013)
Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis
J. A. Hirst et al.
DIABETOLOGIA (2013)
Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial
Burkhard Goeke et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
STATISTICAL QUESTION Prospective cohort studies: advantages and disadvantages
Philip Sedgwick
BMJ-BRITISH MEDICAL JOURNAL (2013)
Cardiovascular Effects of Diabetes Drugs: Emerging From the Dark Ages
Steven E. Nissen
ANNALS OF INTERNAL MEDICINE (2012)
Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus A Cohort Study
Christianne L. Roumie et al.
ANNALS OF INTERNAL MEDICINE (2012)
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
Baptist Gallwitz et al.
LANCET (2012)
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
Baptist Gallwitz et al.
LANCET (2012)
Effect of Antihyperglycemic Agents Added to Metformin and a Sulfonylurea on Glycemic Control and Weight Gain in Type 2 Diabetes: A Network Meta-analysis
Jorge L. Gross et al.
ANNALS OF INTERNAL MEDICINE (2011)
Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin
Scott Klarenbach et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2011)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck et al.
DIABETES CARE (2011)
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
A. Garber et al.
DIABETES OBESITY & METABOLISM (2011)
Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus
Ligia Petrica et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
Tina Ken Schramm et al.
EUROPEAN HEART JOURNAL (2011)
Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes
Kohei Kaku et al.
JOURNAL OF DIABETES INVESTIGATION (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
Hertzel C. Gerstein et al.
CIRCULATION (2010)
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
D. R. Matthews et al.
DIABETES OBESITY & METABOLISM (2010)
A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study
C. Filozof et al.
DIABETIC MEDICINE (2010)
Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
Olivia J. Phung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2009)
Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naive Patients with Type 2 Diabetes
J. E. Foley et al.
HORMONE AND METABOLIC RESEARCH (2009)
Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial
Ligia Petrica et al.
WIENER KLINISCHE WOCHENSCHRIFT (2009)
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Ioanna Tzoulaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Undue reliance on I2 in assessing heterogeneity may mislead
Gerta Ruecker et al.
BMC MEDICAL RESEARCH METHODOLOGY (2008)
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies
Ajay D. Rao et al.
DIABETES CARE (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis
Jorn Wetterslev et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone
A. Hamann et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2008)
Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death
George A. Diamond et al.
ANNALS OF INTERNAL MEDICINE (2007)
Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis
Philip D. Home et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results
S. Ristic et al.
DIABETES OBESITY & METABOLISM (2007)
A systematic review and meta-analysis of hypoglycemia and cardiovascular event - A comparison of glyburide with other secretagogues and with insulin
Azim S. Gangji et al.
DIABETES CARE (2007)
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Michael J. Bradburn et al.
STATISTICS IN MEDICINE (2007)
Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice
Markku Vaehaetalo et al.
SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE (2007)
A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes
Markolf Hanefeld et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial
Theodore Mazzone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus
Rajeev Jain et al.
PHARMACOTHERAPY (2006)
Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria
Tsukasa Nakamura et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2006)
Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics
A. M. Abbatecola et al.
NEUROLOGY (2006)
Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin
J Gerich et al.
DIABETES CARE (2005)
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data
MJ Sweeting et al.
STATISTICS IN MEDICINE (2004)
Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study
S Madsbad et al.
DIABETIC MEDICINE (2001)
Share Paper
